Cartherics Pty has announced that it has been awarded a $300K G-Rex grant to support clinical manufacturing of its lead product CTH-401 for upcoming clinical trials.
SpliceBio has announced that the U.S. Food & Drug Administration (FDA) has cleared its investigational new drug (IND) application for lead program SB-007.
Michael Burkhard and Amr Eltablawi, Hexagon Asset Lifecycle Intelligence, delve into the top trends shaping pharmaceutical and life sciences operations in 2025.
Owkin has launched its latest report, State of the Nation: Opportunities and Challenges for Digital Pathology and AI Solutions, exploring the evolving landscape of digital pathology and AI in healthcare in the UK.
AMSBIO has implemented a program of investment to support the students at Penn State Lehigh Valley, part of Pennsylvania State University, in their transformative Course-based Undergraduate Research Experience (CURE) program.
UK contract development and manufacturing organisation (CDMO) Upperton, continues its growth with the appointment of Lorna Patrick as chief operating officer.
The Gabriel-Chemie Group has announced the opening of a new warehouse that will now serve as the central logistics hub for the entire Gabriel-Chemie group.
NeoPhore, a small molecule neoantigen immuno-oncology company, has announced the appointment of Michael Shih as chief executive officer (CEO) and to the board of directors, effective immediately.
Investors worldwide are scouring for their next big win after the door to the extremely lucrative obesity market was opened by pharmaceutical giants Novo Nordisk and Eli Lilly. Now benefiting on the Swedish stock exchange is a smaller biotech company
Gerresheimer announces that the US Food and Drug Administration (FDA) granted SQ Innovation Tentative Approval for Lasix ONYU for the home treatment of fluid overload in congestive heart failure.
